Global ETD Search
Search theses and dissertations gathered from participating repositories worldwide. Every result links back to the library that holds it. No account is needed.
Results
Showing 1 to 8 of 8 for “"FOLFOX"”.
-
Which Gene is a Dominant Predictor of Response during FOLFOX Chemotherapy for the Treatment of Metastatic Colorectal Cancer, MTHFR or XRCC1 Gene?
"국문요약 ------------------------------------------- i 차례 ----------------------------------------------- iv 그림 차례 ------------------------------------------- v 표 차례---------------------------------------------- vi I. 서론 ------------------------------------------ 1 II. 연구대상 및 …
-
Expression of Bax Predicts Outcome in Advanced Gastric Cancer Patients Treated With 5-fluorouracil and Platinum Palliative Chemotherapy
… patients) or 5-FU, leucovorin, and oxaliplatin (FOLFOX) (72 patients). Pretreatment tumor biopsy specimens were analyzed for Bax, ERCC1, and TS expression by immunohistochemistry. Results: High expression of Bax, ERCC1 and TS was observed in 49 (38%), 60 (47%), and 48 (38%) patients, …
-
현미부수체 상태에 따른 결장암의 예후와 보조항암요법과의 상관관계
… 상태에 따른 결장암의 특성을 분석하였으며, 75명의 3기 결장암 환자를 대상으로 FOLFOX 또는 capecitabine을 투여한 결과를 후향적으로 분석하였다. MSI 결장암의 경우 5년 생존율은 비슷하였으나 (92.3% vs 85.5% p=0.608) 원발종양이 근위부에 위치하고 (86.7% vs 42.3% p<0.001) 병리학적으로 점액성암의 빈도가 높고 암세포의 분화도가 좋게 나왔다. (p<0.001) 3기 결장암에서 FOLFOX치료를 받은 환자군은 capecitabine 투여를 받은 환자군보다 유의한 생존율 …
-
Tailored chemotherapy based on genomic polymorphisms for metastatic colorectal cancer treated with 5-fluorouracil plus oxaliplatin or irinotecan in Korean patients
배경: 옥살리플라틴과 이리노테칸은 전이성 대장암 환자에서 5-FU와 함께 투여하여 FOLFOX 또는 FOLFIRI용법으로 일차치료로서 가장 많이 사용되는 항암제이다. 본 연구의 목적은 전이성 대장암 환자에서 전향적 연구로서 항암제와 연관된 유전자 다형성을 분석하고 환자에 맞는 약제를 선택하여 일차치료를 진행하여 이에 대한 반응도를 알아보기로 하였다. 방법: 50명의 전이성 대장암 환자에서 말초혈액을 통해 유전자 다형성을 분석하였다. PCR-based RFLP 방법을 사용하여 TS, MTHFR-977, XPD-751, …
-
Anticancer Activity of Natural Health Products (Dandelion Root, Lemongrass, and Hibiscus Extracts); A Study of Efficacy, Interaction, and Mechanism of Action
… reduce tumour burden and LGE was able to enhance FOLFOX activity. Thus, the implementation of these well-tolerated extracts in adjuvant therapies could be a selective and efficacious approach to cancer treatment. These findings provide scientific validation to support the safe and effective use of …
-
An exploration of the patients' lived experience with antineoplastic medicines for colorectal cancer in Malta.
… a six month cycle of antineoplastic medicines (FOLFOX or XELOX) for the management of colorectal cancer. In parallel, another longitudinal qualitative study was conducted for Phase III by interviews with significant others nominated by patients participating in Phase II. This phase aimed to …
-
A colorectalis daganatok farmakoterápiája napjainkban
A colorectalis daganatok napjainkban is az egyik leggyakrabban előforduló, a világ szinte minden területén fellelhető daganatok. Bár elsődleges kezelésüket a műtéti úton történő eltávolítás jelenti, mára már jelentős lépéseket tett az orvostudomány a farmakoterápiai szerek minél hatékonyabb …
-
Identification of novel determinants of primary and acquired resistance to EGFR-targeted therapies in colorectal cancer
… or irinotecan to 5-FU and folinic acid (FOLFOX and FOLFIRI respectively) was determined to increase this response rate and overall survival to 40-50% and 15-19 months respectively. These combination chemotherapeutics subsequently became the standard of care (SOC) treatment for stage IV …